Author: "Hansson, Markus" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Hansson, Markus"' showing total 613 results

Start Over Author "Hansson, Markus"

613 results on '"Hansson, Markus"'

101. Additional file 1: of Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes

Author: Went, Molly, Kinnersley, Ben, Sud, Amit, Johnson, David, Weinhold, Niels, FĂśrsti, Asta, Duin, Mark, Orlando, Giulia, Mitchell, Jonathan, Kuiper, Rowan, Walker, Brian, Gregory, Walter, Hoffmann, Per, Jackson, Graham, NĂśthen, Markus, Filho, Miguel Silva, Thomsen, Hauke, Broyl, Annemiek, Davies, Faith, Thorsteinsdottir, Unnur, Hansson, Markus, Kaiser, Martin, Sonneveld, Pieter, Goldschmidt, Hartmut, Stefansson, Kari, Hemminki, Kari, BjĂśrn Nilsson, Morgan, Gareth, and Houlston, Richard
Abstract: Table S1. Genes significantly associated with risk of multiple myeloma. Table S2. New and previously implicated1-5 genes at each genome wide significant multiple myeloma locus. Table S3. Quality control filters applied to samples from the seven published GWAS. Table S4. Quality control filters applied to SNPs from each GWAS. Table S5. MM GWAS risk SNPs. Figure S1. Quantile-Quantile Plots of â log10(P-value) associations. Figure S2. TWAS power plot in EBV-transformed lymphocytes. (DOCX 1515 kb)
Published: 2019
Full Text: View/download PDF

102. Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers

Author: Hansson, Markus, Jerkeman, Mats, and Dictor, Michael
Published: 2007

103. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Author: Schmidt, Amand F., Holmes, Michael V., Preiss, David, Swerdlow, Daniel I., Denaxas, Spiros, Fatemifar, Ghazaleh, Faraway, Rupert, Finan, Chris, Valentine, Dennis, Fairhurst-Hunter, Zammy, Hartwig, Fernando Pires, Horta, Bernardo Lessa, Hypponen, Elina, Power, Christine, Moldovan, Max, van Iperen, Erik, Hovingh, Kees, Demuth, Ilja, Norman, Kristina, Steinhagen-Thiessen, Elisabeth, Demuth, Juri, Bertram, Lars, Lill, Christina M., Coassin, Stefan, Willeit, Johann, Kiechl, Stefan, Willeit, Karin, Mason, Dan, Wright, John, Morris, Richard, Wanamethee, Goya, Whincup, Peter, Ben-Shlomo, Yoav, McLachlan, Stela, Price, Jackie F., Kivimaki, Mika, Welch, Catherine, Sanchez-Galvez, Adelaida, Marques-Vidal, Pedro, Nicolaides, Andrew, Panayiotou, Andrie G., Onland-Moret, N. Charlotte, van der Schouw, Yvonne T., Matullo, Giuseppe, Fiorito, Giovanni, Guarrera, Simonetta, Sacerdote, Carlotta, Wareham, Nicholas J., Langenberg, Claudia, Scott, Robert A., Luan, Jian'an, Bobak, Martin, Malyutina, Sofia, Pajak, Andrzej, Kubinova, Ruzena, Tamosiunas, Abdonas, Pikhart, Hynek, Grarup, Niels, Pedersen, Oluf, Hansen, Torben, Linneberg, Allan, Jess, Tine, Cooper, Jackie, Humphries, Steve E., Brilliant, Murray, Kitchner, Terrie, Hakonarson, Hakon, Carrell, David S., McCarty, Catherine A., Lester, Kirchner H., Larson, Eric B., Crosslin, David R., de Andrade, Mariza, Roden, Dan M., Denny, Joshua C., Carty, Cara, Hancock, Stephen, Attia, John, Holliday, Elizabeth, Scott, Rodney, Schofield, Peter, O'Donnell, Martin, Yusuf, Salim, Chong, Michael, Pare, Guillaume, van der Harst, Pim, Said, M. Abdullah, Eppinga, Ruben N., Verweij, Niek, Snieder, Harold, Christen, Tim, Mook-Kanamori, D. O., Gustafsson, Stefan, Lind, Lars, Ingelsson, Erik, Pazoki, Raha, Franco, Oscar, Hofman, Albert, Uitterlinden, Andre, Dehghan, Abbas, Teumer, Alexander, Baumeister, Sebastian, Doerr, Marcus, Lerch, Markus M., Voelker, Uwe, Voelzke, Henry, Ward, Joey, Pell, Jill P., Meade, Tom, Christophersen, Ingrid E., Maitland-van der Zee, Anke H., Baranova, Ekaterina V., Young, Robin, Ford, Ian, Campbell, Archie, Padmanabhan, Sandosh, Bots, Michiel L., Grobbee, Diederick E., Froguel, Philippe, Thuillier, Dorothee, Roussel, Ronan, Bonnefond, Amelie, Cariou, Bertrand, Smart, Melissa, Bao, Yanchun, Kumari, Meena, Mahajan, Anubha, Hopewell, Jemma C., Seshadri, Sudha, Dale, Caroline, Costa, Rui Providencia E., Ridker, Paul M., Chasman, Daniel I., Reiner, Alex P., Ritchie, Marylyn D., Lange, Leslie A., Cornish, Alex J., Dobbins, Sara E., Hemminki, Kari, Kinnersley, Ben, Sanson, Marc, Labreche, Karim, Simon, Matthias, Bondy, Melissa, Law, Philip, Speedy, Helen, Allan, James, Li, Ni, Went, Molly, Weinhold, Niels, Morgan, Gareth, Sonneveld, Pieter, Nilsson, Bjorn, Goldschmidt, Hartmut, Sud, Amit, Engert, Andreas, Hansson, Markus, Hemingway, Harry, Asselbergs, Folkert W., Patel, Riyaz S., Keating, Brendan J., Sattar, Naveed, Houlston, Richard, Casas, Juan P., Hingorani, Aroon D., Schmidt, Amand F., Holmes, Michael V., Preiss, David, Swerdlow, Daniel I., Denaxas, Spiros, Fatemifar, Ghazaleh, Faraway, Rupert, Finan, Chris, Valentine, Dennis, Fairhurst-Hunter, Zammy, Hartwig, Fernando Pires, Horta, Bernardo Lessa, Hypponen, Elina, Power, Christine, Moldovan, Max, van Iperen, Erik, Hovingh, Kees, Demuth, Ilja, Norman, Kristina, Steinhagen-Thiessen, Elisabeth, Demuth, Juri, Bertram, Lars, Lill, Christina M., Coassin, Stefan, Willeit, Johann, Kiechl, Stefan, Willeit, Karin, Mason, Dan, Wright, John, Morris, Richard, Wanamethee, Goya, Whincup, Peter, Ben-Shlomo, Yoav, McLachlan, Stela, Price, Jackie F., Kivimaki, Mika, Welch, Catherine, Sanchez-Galvez, Adelaida, Marques-Vidal, Pedro, Nicolaides, Andrew, Panayiotou, Andrie G., Onland-Moret, N. Charlotte, van der Schouw, Yvonne T., Matullo, Giuseppe, Fiorito, Giovanni, Guarrera, Simonetta, Sacerdote, Carlotta, Wareham, Nicholas J., Langenberg, Claudia, Scott, Robert A., Luan, Jian'an, Bobak, Martin, Malyutina, Sofia, Pajak, Andrzej, Kubinova, Ruzena, Tamosiunas, Abdonas, Pikhart, Hynek, Grarup, Niels, Pedersen, Oluf, Hansen, Torben, Linneberg, Allan, Jess, Tine, Cooper, Jackie, Humphries, Steve E., Brilliant, Murray, Kitchner, Terrie, Hakonarson, Hakon, Carrell, David S., McCarty, Catherine A., Lester, Kirchner H., Larson, Eric B., Crosslin, David R., de Andrade, Mariza, Roden, Dan M., Denny, Joshua C., Carty, Cara, Hancock, Stephen, Attia, John, Holliday, Elizabeth, Scott, Rodney, Schofield, Peter, O'Donnell, Martin, Yusuf, Salim, Chong, Michael, Pare, Guillaume, van der Harst, Pim, Said, M. Abdullah, Eppinga, Ruben N., Verweij, Niek, Snieder, Harold, Christen, Tim, Mook-Kanamori, D. O., Gustafsson, Stefan, Lind, Lars, Ingelsson, Erik, Pazoki, Raha, Franco, Oscar, Hofman, Albert, Uitterlinden, Andre, Dehghan, Abbas, Teumer, Alexander, Baumeister, Sebastian, Doerr, Marcus, Lerch, Markus M., Voelker, Uwe, Voelzke, Henry, Ward, Joey, Pell, Jill P., Meade, Tom, Christophersen, Ingrid E., Maitland-van der Zee, Anke H., Baranova, Ekaterina V., Young, Robin, Ford, Ian, Campbell, Archie, Padmanabhan, Sandosh, Bots, Michiel L., Grobbee, Diederick E., Froguel, Philippe, Thuillier, Dorothee, Roussel, Ronan, Bonnefond, Amelie, Cariou, Bertrand, Smart, Melissa, Bao, Yanchun, Kumari, Meena, Mahajan, Anubha, Hopewell, Jemma C., Seshadri, Sudha, Dale, Caroline, Costa, Rui Providencia E., Ridker, Paul M., Chasman, Daniel I., Reiner, Alex P., Ritchie, Marylyn D., Lange, Leslie A., Cornish, Alex J., Dobbins, Sara E., Hemminki, Kari, Kinnersley, Ben, Sanson, Marc, Labreche, Karim, Simon, Matthias, Bondy, Melissa, Law, Philip, Speedy, Helen, Allan, James, Li, Ni, Went, Molly, Weinhold, Niels, Morgan, Gareth, Sonneveld, Pieter, Nilsson, Bjorn, Goldschmidt, Hartmut, Sud, Amit, Engert, Andreas, Hansson, Markus, Hemingway, Harry, Asselbergs, Folkert W., Patel, Riyaz S., Keating, Brendan J., Sattar, Naveed, Houlston, Richard, Casas, Juan P., and Hingorani, Aroon D.
Abstract: Background: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9. Methods: Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration. Results: The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57; 1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2 diabetes mellitus (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer's disease - outcomes for which large-scale trial data were unavailable. Conclusions: Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown; although precision was moderate.
Published: 2019
Full Text: View/download PDF

104. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author: Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, Janakiram, Murali, Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, and Janakiram, Murali
Published: 2019

105. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Author: Planningssecretariaat HCK, Onderzoek Precision medicine, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Kanker, Brain, Cancer, Cardiovasculaire Epidemiologie, Epi Methoden Team 6, Aios en Stafsecr. Cardiologie, Cardiovasculaire Epi Team 5, Cardiovasculaire Epi Team 9, Team Medisch, Schmidt, Amand F., Holmes, Michael V., Preiss, David, Swerdlow, Daniel I., Denaxas, Spiros, Fatemifar, Ghazaleh, Faraway, Rupert, Finan, Chris, Valentine, Dennis, Fairhurst-Hunter, Zammy, Hartwig, Fernando Pires, Horta, Bernardo Lessa, Hypponen, Elina, Power, Christine, Moldovan, Max, Van Iperen, Erik, Hovingh, Kees, Demuth, Ilja, Norman, Kristina, Steinhagen-Thiessen, Elisabeth, Demuth, Juri, Bertram, Lars, Lill, Christina M., Coassin, Stefan, Willeit, Johann, Kiechl, Stefan, Willeit, Karin, Mason, Dan, Wright, John, Morris, Richard, Wanamethee, Goya, Whincup, Peter, Ben-Shlomo, Yoav, McLachlan, Stela, Price, Jackie F., Kivimaki, Mika, Welch, Catherine, Sanchez-Galvez, Adelaida, Marques-Vidal, Pedro, Nicolaides, Andrew, Panayiotou, Andrie G., Onland-Moret, N. Charlotte, Van Der Schouw, Yvonne T., Matullo, Giuseppe, Fiorito, Giovanni, Guarrera, Simonetta, Sacerdote, Carlotta, Wareham, Nicholas J., Langenberg, Claudia, Scott, Robert A., Luan, Jian'An, Bobak, Martin, Malyutina, Sofia, Pajak, Andrzej, Kubinova, Ruzena, Tamosiunas, Abdonas, Pikhart, Hynek, Grarup, Niels, Pedersen, Oluf, Hansen, Torben, Linneberg, Allan, Jess, Tine, Cooper, Jackie, Humphries, Steve E., Brilliant, Murray, Kitchner, Terrie, Hakonarson, Hakon, Carrell, David S., McCarty, Catherine A., Lester, Kirchner H., Larson, Eric B., Crosslin, David R., De Andrade, Mariza, Roden, Dan M., Denny, Joshua C., Carty, Cara, Hancock, Stephen, Attia, John, Holliday, Elizabeth, Scott, Rodney, Schofield, Peter, O'Donnell, Martin, Yusuf, Salim, Chong, Michael, Pare, Guillaume, Van Der Harst, Pim, Said, M. Abdullah, Eppinga, Ruben N., Verweij, Niek, Snieder, Harold, Christen, Tim, Mook-Kanamori, D. O., Gustafsson, Stefan, Lind, Lars, Ingelsson, Erik, Pazoki, Raha, Franco, Oscar, Hofman, Albert, Uitterlinden, Andre, Dehghan, Abbas, Teumer, Alexander, Baumeister, Sebastian, Dörr, Marcus, Lerch, Markus M., Völker, Uwe, Völzke, Henry, Ward, Joey, Pell, Jill P., Meade, Tom, Christophersen, Ingrid E., Maitland-Van Der Zee, Anke H., Baranova, Ekaterina V., Young, Robin, Ford, Ian, Campbell, Archie, Padmanabhan, Sandosh, Bots, Michiel L., Grobbee, Diederick E., Froguel, Philippe, Thuillier, Dorothée, Roussel, Ronan, Bonnefond, Amélie, Cariou, Bertrand, Smart, Melissa, Bao, Yanchun, Kumari, Meena, Mahajan, Anubha, Hopewell, Jemma C., Seshadri, Sudha, Dale, Caroline, Costa, Rui Providencia E., Ridker, Paul M., Chasman, Daniel I., Reiner, Alex P., Ritchie, Marylyn D., Lange, Leslie A., Cornish, Alex J., Dobbins, Sara E., Hemminki, Kari, Kinnersley, Ben, Sanson, Marc, Labreche, Karim, Simon, Matthias, Bondy, Melissa, Law, Philip, Speedy, Helen, Allan, James, Li, Ni, Went, Molly, Weinhold, Niels, Morgan, Gareth, Sonneveld, Pieter, Nilsson, Björn, Goldschmidt, Hartmut, Sud, Amit, Engert, Andreas, Hansson, Markus, Hemingway, Harry, Asselbergs, Folkert W., Patel, Riyaz S., Keating, Brendan J., Sattar, Naveed, Houlston, Richard, Casas, Juan P., Hingorani, Aroon D., Planningssecretariaat HCK, Onderzoek Precision medicine, Cardiovasculaire Epi Team 3, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, JC onderzoeksprogramma Kanker, Brain, Cancer, Cardiovasculaire Epidemiologie, Epi Methoden Team 6, Aios en Stafsecr. Cardiologie, Cardiovasculaire Epi Team 5, Cardiovasculaire Epi Team 9, Team Medisch, Schmidt, Amand F., Holmes, Michael V., Preiss, David, Swerdlow, Daniel I., Denaxas, Spiros, Fatemifar, Ghazaleh, Faraway, Rupert, Finan, Chris, Valentine, Dennis, Fairhurst-Hunter, Zammy, Hartwig, Fernando Pires, Horta, Bernardo Lessa, Hypponen, Elina, Power, Christine, Moldovan, Max, Van Iperen, Erik, Hovingh, Kees, Demuth, Ilja, Norman, Kristina, Steinhagen-Thiessen, Elisabeth, Demuth, Juri, Bertram, Lars, Lill, Christina M., Coassin, Stefan, Willeit, Johann, Kiechl, Stefan, Willeit, Karin, Mason, Dan, Wright, John, Morris, Richard, Wanamethee, Goya, Whincup, Peter, Ben-Shlomo, Yoav, McLachlan, Stela, Price, Jackie F., Kivimaki, Mika, Welch, Catherine, Sanchez-Galvez, Adelaida, Marques-Vidal, Pedro, Nicolaides, Andrew, Panayiotou, Andrie G., Onland-Moret, N. Charlotte, Van Der Schouw, Yvonne T., Matullo, Giuseppe, Fiorito, Giovanni, Guarrera, Simonetta, Sacerdote, Carlotta, Wareham, Nicholas J., Langenberg, Claudia, Scott, Robert A., Luan, Jian'An, Bobak, Martin, Malyutina, Sofia, Pajak, Andrzej, Kubinova, Ruzena, Tamosiunas, Abdonas, Pikhart, Hynek, Grarup, Niels, Pedersen, Oluf, Hansen, Torben, Linneberg, Allan, Jess, Tine, Cooper, Jackie, Humphries, Steve E., Brilliant, Murray, Kitchner, Terrie, Hakonarson, Hakon, Carrell, David S., McCarty, Catherine A., Lester, Kirchner H., Larson, Eric B., Crosslin, David R., De Andrade, Mariza, Roden, Dan M., Denny, Joshua C., Carty, Cara, Hancock, Stephen, Attia, John, Holliday, Elizabeth, Scott, Rodney, Schofield, Peter, O'Donnell, Martin, Yusuf, Salim, Chong, Michael, Pare, Guillaume, Van Der Harst, Pim, Said, M. Abdullah, Eppinga, Ruben N., Verweij, Niek, Snieder, Harold, Christen, Tim, Mook-Kanamori, D. O., Gustafsson, Stefan, Lind, Lars, Ingelsson, Erik, Pazoki, Raha, Franco, Oscar, Hofman, Albert, Uitterlinden, Andre, Dehghan, Abbas, Teumer, Alexander, Baumeister, Sebastian, Dörr, Marcus, Lerch, Markus M., Völker, Uwe, Völzke, Henry, Ward, Joey, Pell, Jill P., Meade, Tom, Christophersen, Ingrid E., Maitland-Van Der Zee, Anke H., Baranova, Ekaterina V., Young, Robin, Ford, Ian, Campbell, Archie, Padmanabhan, Sandosh, Bots, Michiel L., Grobbee, Diederick E., Froguel, Philippe, Thuillier, Dorothée, Roussel, Ronan, Bonnefond, Amélie, Cariou, Bertrand, Smart, Melissa, Bao, Yanchun, Kumari, Meena, Mahajan, Anubha, Hopewell, Jemma C., Seshadri, Sudha, Dale, Caroline, Costa, Rui Providencia E., Ridker, Paul M., Chasman, Daniel I., Reiner, Alex P., Ritchie, Marylyn D., Lange, Leslie A., Cornish, Alex J., Dobbins, Sara E., Hemminki, Kari, Kinnersley, Ben, Sanson, Marc, Labreche, Karim, Simon, Matthias, Bondy, Melissa, Law, Philip, Speedy, Helen, Allan, James, Li, Ni, Went, Molly, Weinhold, Niels, Morgan, Gareth, Sonneveld, Pieter, Nilsson, Björn, Goldschmidt, Hartmut, Sud, Amit, Engert, Andreas, Hansson, Markus, Hemingway, Harry, Asselbergs, Folkert W., Patel, Riyaz S., Keating, Brendan J., Sattar, Naveed, Houlston, Richard, Casas, Juan P., and Hingorani, Aroon D.
Published: 2019

106. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author: MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, Janakiram, Murali, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, and Janakiram, Murali
Published: 2019

107. Targeting proteins to secretory lysosomes of natural killer cells as a principle for immunoregulation

Author: Hansson, Markus, Jönsson, Sofia, Persson, Ann-Maj, Calafat, Jero, Tapper, Hans, and Olsson, Inge
Published: 2003
Full Text: View/download PDF

108. Health-related quality of life in multiple myeloma patients with first relapse treated with Carfilzomib-based re-induction and salvage autologous stem cell transplantation:data from a Nordic phase II trial

Author: Eshoj, Henrik Rode, Nielsen, Lene Kongsgaard, Schjesvold, Fredrik, Abildgaard, Niels, Nahi, Hareth, Andersen, Niels Frost, Vangsted, Annette Juul, Helleberg, Carsten, Frolund, Ulf Christian, Axelsson, Per, Stromberg, Olga, Cecilie Hveding Blimark, Carlson, Kristina, Waage, Anders, Remes, Kari, Peceliunas, Valdas, Guldbrandsen, Nina, Hansson, Markus, and Gregersen, Henrik
Published: 2018
Full Text: View/download PDF

109. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology

Author: Went, Molly, Sud, Amit, Speedy, Helen, Sunter, Nicola J., Försti, Asta, Law, Philip J., Johnson, David C., Mirabella, Fabio, Holroyd, Amy, Li, Ni, Orlando, Giulia, Weinhold, Niels, van Duin, Mark, Chen, Bowang, Mitchell, Jonathan S., Mansouri, Larry, Juliusson, Gunnar, Smedby, Karin E, Jayne, Sandrine, Majid, Aneela, Dearden, Claire, Allsup, David J., Bailey, James R., Pratt, Guy, Pepper, Chris, Fegan, Chris, Rosenquist, Richard, Kuiper, Rowan, Stephens, Owen W., Bertsch, Uta, Broderick, Peter, Einsele, Hermann, Gregory, Walter M., Hillengass, Jens, Hoffmann, Per, Jackson, Graham H., Jöckel, Karl-Heinz, Nickel, Jolanta, Nöthen, Markus M., da Silva Filho, Miguel Inacio, Thomsen, Hauke, Walker, Brian A., Broyl, Annemiek, Davies, Faith E., Hansson, Markus, Goldschmidt, Hartmut, Dyer, Martin J. S., Kaiser, Martin, Sonneveld, Pieter, Morgan, Gareth J., Hemminki, Kari, Nilsson, Björn, Catovsky, Daniel, Allan, James M., Houlston, Richard S., and Hematology
Subjects: Cancer och onkologi, Genetic Linkage, Quantitative Trait Loci, Medizin, Hematology, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Leukemia, Lymphocytic, Chronic, B-Cell, Polymorphism, Single Nucleotide, Article, Linkage Disequilibrium, Organ Specificity, Cancer and Oncology, hemic and lymphatic diseases, Case-Control Studies, Databases, Genetic, Humans, Genetic Predisposition to Disease, Hematologi, Multiple Myeloma, Alleles, Genetic Association Studies, Genome-Wide Association Study
Abstract: The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) genome-wide association study (GWAS) data sets, totalling 11,734 cases and 29,468 controls. A significant genetic correlation between these two B-cell malignancies was shown (R g = 0.4, P = 0.0046). Furthermore, four of the 45 known CLL risk loci were shown to associate with MM risk and five of the 23 known MM risk loci associate with CLL risk. By integrating eQTL, Hi-C and ChIP-seq data, we show that these pleiotropic risk loci are enriched for B-cell regulatory elements and implicate B-cell developmental genes. These data identify shared biological pathways influencing the development of CLL and, MM and further our understanding of the aetiological basis of these B-cell malignancies.
Published: 2018

110. Carfilzomib-Cyclophosphamide-Dexamethasone induction and salvage ASCT transplant-eligible multiple myeloma with firs trelapse after upfront ASCT

Author: Gregersen, Henrik, Schjesvold, Fredrik H., Peceliunas, Valdas, Remes, Kari, Abildgaard , Niels, Nahi, Hareth, Andersen, Niels Frost, Vangsted, Annette Juul, Klausen, Tobias Wirenfeldt, Helleberg, Carsten, Frølund, Ulf, Axelsson, Per, Stromberg, Olga, Blimark, Ceciliie, Carlson, Kristina, Waage, Anders, Hansson, Markus, and Gulbrandsen, Nina
Published: 2018

111. Tracking and Serving Geolocated Ads, Load Balancing, and Scaling of Server Resources

Author: Hansson, Markus
Subjects: Docker, Ads, Geolocation, Statistics, Advertisement, ECS, Load Balancing, Datorteknik, AWS, Server, ELB, Amazon Web Service, Server Scaling, Computer Engineering, Container
Abstract: This thesis explores the creation of a scaling, containerized, advertisement server that will be used by Gold Town Games AB to better integrate ads into their application(s). The server is built as a Docker image that will be used to create server instances on AWS Elastic Container Service for automatic scaling and server resource configuration. The server was created with the intention that GTG will have full control over what advertisements are shown in their application(s) and to seamlessly integrate sponsored logos onto jerseys or sports fields. This will not only serve as a source of income with advertisers paying for ad space, but it will also make the game elements more realistic as we have come to expect teams and stadiums to be sponsored and plastered with company logos. Another important part when displaying advertisement is to track statistics for the ads, since without a way to show advertisers that their ads are shown and that they are generating engagement it is very hard to sell the ad space. Detta examensarbete utforskar skapandet av en skalbar, containerbaserad, reklamserver som kommer användas av Gold Town Games AB för att integrera reklam i deras applikation(er). Servern är byggd som en Docker-bild som används för att skapa instanser på AWS Elastic Container Service för automatisk skalning och serverresurshantering. Servern är utvecklad med tanken att GTG ska ha full kontroll över vilken reklam som visas i deras applikation(er) och för att kunna lägga till sponsrade loggor på matchtröjor och i arenor. Detta är inte bara en extra form av inkomst, då annonsörer betalar för reklamplatser, utan hjälper även till att få delar av spelen att kännas mer realistiska då vi är vana att lag och arenor är sponsrade och fulla av företagsloggor. En annan viktig del när man visar reklam är att kunna spara statistik för den, eftersom det skulle vara väldigt svårt att sälja reklamplatser utan att kunna visa att folk faktiskt ser reklamen.
Published: 2018

112. Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark

Author: Abildgaard, Niels, primary, Waage, Anders, additional, Hansson, Markus, additional, Anttila, Pekka, additional, Szilcz, Mate, additional, Ma, Yuanjun, additional, Hass Rubin, Katrine, additional, von Arx, Lill-Brith, additional, Ørstavik, Sigurd, additional, Bent-Ennakhil, Nawal, additional, Freilich, Jonatan, additional, Gavini, François, additional, and Green, Anders, additional
Published: 2019
Full Text: View/download PDF

113. A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Author: Gregersen, Henrik, primary, Peceliunas, Valdas, primary, Remes, Kari, primary, Schjesvold, Fredrik H., primary, Abildgaard, Niels, primary, Nahi, Hareth, primary, Andersen, Niels Frost, primary, Vangsted, Annette Juul, primary, Klausen, Tobias Wirenfeldt, primary, Helleberg, Carsten, primary, Carlson, Kristina, primary, Frølund, Ulf Christian, primary, Axelsson, Per, primary, Stromberg, Olga, primary, Blimark, Cecilie Hveding, primary, Linder, Olle, primary, Tsykunova, Galina, primary, Waage, Anders, primary, Hansson, Markus, primary, and Gulbrandsen, Nina, primary
Published: 2019
Full Text: View/download PDF

114. Utilizing Multiple Linked Populations Registers to Estimate Incidence and Prevalence of Multiple Myeloma in Sweden and Denmark from the Real-World HUMANS Study

Author: Hansson, Markus, primary, Abildgaard, Niels, additional, Waage, Anders, additional, Anttila, Pekka, additional, Green, Anders, additional, Hass Rubin, Katrine, additional, von Arx, Lill-Brith, additional, Szilcz, Mate, additional, Ma, Yuanjun, additional, Ørstavik, Sigurd, additional, Bent-Ennakhil, Nawal, additional, Freilich, Jonatan, additional, and Gavini, François, additional
Published: 2019
Full Text: View/download PDF

115. Prognostic and Predictive Performance of SKY92 Combined with R-ISS in Elderly Multiple Myeloma Patients in The Hovon-87/NMSG-18 Study

Author: Kuiper, Rowan, primary, Broijl, Annemiek, additional, van Duin, Mark, additional, van Vliet, Martin H., additional, Levin, Mark-David, additional, van Beers, Erik H., additional, Van der Holt, Bronno, additional, Visser, Heleen, additional, Hansson, Markus, additional, van der Velden, Annette W.G., additional, Dumee, Belinda, additional, Vermeulen, Michael, additional, Koenders, Jasper, additional, Beverloo, H. Berna, additional, Stevens-Kroef, Marian, additional, Sonneveld, Pieter, additional, Waage, Anders, additional, and Zweegman, Sonja, additional
Published: 2019
Full Text: View/download PDF

116. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Author: Nielsen, Lene Kongsgaard, primary, Stege, Claudia, additional, Lissenberg-Witte, Birgit, additional, van der Holt, Bronno, additional, Mellqvist, Ulf-Henrik, additional, Salomo, Morten, additional, Bos, Gerard, additional, Levin, Mark-David, additional, Visser-Wisselaar, Heleen, additional, Hansson, Markus, additional, van der Velden, Annette, additional, Deenik, Wendy, additional, Coenen, Juleon, additional, Hinge, Maja, additional, Klein, Saskia, additional, Tanis, Bea, additional, Szatkowski, Damian, additional, Brouwer, Rolf, additional, Westerman, Matthijs, additional, Leys, Rineke, additional, Sinnige, Harm, additional, Haukås, Einar, additional, van der Hem, Klaas, additional, Durian, Marc, additional, Gimsing, Peter, additional, van de Donk, Niels, additional, Sonneveld, Pieter, additional, Waage, Anders, additional, Abildgaard, Niels, additional, and Zweegman, Sonja, additional
Published: 2019
Full Text: View/download PDF

117. Insights on Multiple Myeloma Treatment Strategies

Author: Mateos, María-Victoria, primary, Ludwig, Heinz, additional, Bazarbachi, Ali, additional, Beksac, Meral, additional, Bladé, Joan, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, Delforge, Michel, additional, Dimopoulos, Meletios A., additional, Facon, Thierry, additional, Geraldes, Catarina, additional, Goldschmidt, Hartmut, additional, Hájek, Roman, additional, Hansson, Markus, additional, Jamroziak, Krzysztof, additional, Leiba, Merav, additional, Masszi, Tamás, additional, Mendeleeva, Larisa, additional, O’Dwyer, Michael, additional, Plesner, Torben, additional, San-Miguel, Jesús F., additional, Straka, Christian, additional, van de Donk, Niels W.C.J., additional, Yong, Kwee, additional, Zver, Samo, additional, Moreau, Philippe, additional, and Sonneveld, Pieter, additional
Published: 2019
Full Text: View/download PDF

118. Health-Related Quality of Life in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients Treated with Either Thalidomide or Lenalidomide-Based Regimen Until Progression (HOVON-87/NMSG18 Study): A Prospective, Open-Label, Multicenter, Randomized, Phase 3 Study

Author: Nielsen, Lene Kongsgaard, primary, Stege, Claudia, additional, Lissenberg-Witte, Birgit, additional, van der Holt, Bronno, additional, Mellqvist, Ulf-Henrik, additional, Salomo, Morten, additional, Bos, Gerard M., additional, Levin, Mark-David, additional, Visser-Wisselaar, Heleen, additional, Hansson, Markus, additional, van der Velden, Annette, additional, Deenik, Wendy, additional, Coenen, Juleon, additional, Hinge, Maja, additional, Klein, Saskia K., additional, Szatkowski, Damian, additional, Westerman, Matthijs, additional, Leys, Rineke, additional, Sinnige, Harm, additional, Haukas, Einar, additional, van der Hem, Klaas, additional, Gimsing, Peter, additional, van de Donk, Niels, additional, Sonneveld, Pieter, additional, Waage, Anders, additional, Abildgaard, Niels, additional, and Zweegman, Sonja, additional
Published: 2019
Full Text: View/download PDF

119. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author: Dimopoulos, Meletios A, primary, Gay, Francesca, additional, Schjesvold, Fredrik, additional, Beksac, Meral, additional, Hajek, Roman, additional, Weisel, Katja Christina, additional, Goldschmidt, Hartmut, additional, Maisnar, Vladimir, additional, Moreau, Philippe, additional, Min, Chang Ki, additional, Pluta, Agnieszka, additional, Chng, Wee-Joo, additional, Kaiser, Martin, additional, Zweegman, Sonja, additional, Mateos, Maria-Victoria, additional, Spencer, Andrew, additional, Iida, Shinsuke, additional, Morgan, Gareth, additional, Suryanarayan, Kaveri, additional, Teng, Zhaoyang, additional, Skacel, Tomas, additional, Palumbo, Antonio, additional, Dash, Ajeeta B, additional, Gupta, Neeraj, additional, Labotka, Richard, additional, Rajkumar, S Vincent, additional, Bar, Daniel, additional, Basso, Alfredo, additional, Fantl, Dorotea, additional, He, Simon, additional, Horvath, Neomi, additional, Lee, Cindy, additional, Rowlings, Phillip, additional, Taylor, Kerry, additional, Cochrane, Tara, additional, Kwok, Fiona, additional, Ramanathan, Sundreswran, additional, Agis, Hermine, additional, Zojer, Niklas, additional, Kentos, Alain, additional, Offner, Fritz, additional, Van Droogenbroeck, Jan, additional, Wu, Ka Lung, additional, Maiolino, Angelo, additional, Martinez, Gracia, additional, Zanella, Karla, additional, Capra, Marcelo, additional, Araújo, Sérgio, additional, Gregora, Evzen, additional, Pour, Ludek, additional, Scudla, Vlastimil, additional, Spicka, Ivan, additional, Abildgaard, Niels, additional, Andersen, Niels, additional, Jensen, Bo Amdi, additional, Helleberg, Carsten, additional, Plesner, Torben, additional, Salomo, Morten, additional, Svirskaite, Asta, additional, Delarue, Richard, additional, Blau, Igor, additional, Schieferdecker, Aneta, additional, Teleanu, Veronica, additional, Munder, Markus, additional, Röllig, Christoph, additional, Salwender, Han-Juergen, additional, Fuhrmann, Stephan, additional, Weisel, Katja, additional, Duerig, Jan, additional, Zeis, Matthias, additional, Klein, Stefan, additional, Reimer, Peter, additional, Schmidt, Christian, additional, Scheid, Christof, additional, Mayer, Karin, additional, Hoffmann, Martin, additional, Sosada, Markus, additional, Dimopoulos, Athanasios, additional, Delimpasi, Sosana, additional, Kyrtsonis, Mary-Christine, additional, Anagnostopoulos, Achilleas, additional, Nagy, Zsolt, additional, Illés, Árpád, additional, Egyed, Miklós, additional, Borbényi, Zita, additional, Mikala, Gabor, additional, Dally, Najib, additional, Horowitz, Netanel, additional, Gutwein, Odit, additional, Nemets, Anatoly, additional, Vaxman, Iuliana, additional, Shvetz, Olga, additional, Trestman, Svetlana, additional, Ruchlemer, Rosa, additional, Nagler, Arnon, additional, Tadmor, Tamar, additional, Rouvio, Ory, additional, Preis, Meir, additional, Cavo, Michele, additional, De Rosa, Luca, additional, Musto, Pellegrino, additional, Cafro, Anna, additional, Tosi, Patrizia, additional, Offidani, Massimo, additional, Corso, Alessandro, additional, Rossi, Giuseppe, additional, Liberati, Anna Marina, additional, Bosi, Alberto, additional, Suzuki, Kenshi, additional, Nakaseko, Chiaki, additional, Ishikawa, Takayuki, additional, Matsumoto, Morio, additional, Nagai, Hirokazu, additional, Sunami, Kazutaka, additional, Chou, Takaaki, additional, Akashi, Koichi, additional, Takezako, Naoki, additional, Hagiwara, Shotaro, additional, Eom, Hyeon Seok, additional, Jo, Deog-Yeon, additional, Kim, Jin Seok, additional, Lee, Jae Hoon, additional, Yoon, Sung Soo, additional, Yoon, Dok Hyun, additional, Kim, Kihyun, additional, Levin, Mark-David, additional, Vellenga, Edo, additional, Minnema, Monique, additional, Waage, Anders, additional, Haukås, Einar, additional, Grosicki, Sebastian, additional, Pluta, Andrzej, additional, Robak, Tadeusz, additional, Marques, Herlander, additional, Bergantim, Rui, additional, Campilho, Fernando, additional, Chng, Wee Joo, additional, Goh, Yeow Tee, additional, McDonald, Andrew, additional, Rapoport, Bernado, additional, Álvarez Rivas, Miguel Angel, additional, De Arriba de La Fuente, Felipe, additional, González Montes, Yolanda, additional, Martin Sanchez, Jesus, additional, Mateos, Maria Victoria, additional, Oriol Rocafiguera, Albert, additional, Rosinol, Laura, additional, San Miguel, Jesús, additional, Pérez de Oteyza, Jaime, additional, Encinas, Cristina, additional, Alegre-Amor, Adrian, additional, López-Guía, Ana, additional, Axelsson, Per, additional, Carlson, Kristina, additional, Stromberg, Olga, additional, Hansson, Markus, additional, Hveding Blimark, Cecile, additional, Mueller, Rouven, additional, Chen, Chih-Cheng, additional, Liu, Ta-Chih, additional, Huang, Shang-Yi, additional, Wang, Po-Nan, additional, Na Nakorn, Thanyaphong, additional, Prayongratana, Kannadit, additional, Unal, Ali, additional, Goker, Hakan, additional, Sonmez, Mehmet, additional, Korenkova, Sybiryna, additional, Chaidos, Aristeidis, additional, Oakervee, Heather, additional, Sati, Hamdi, additional, Benjamin, Reuben, additional, Wechalekar, Ashutosh, additional, Garg, Mamta, additional, Ramasamy, Karthik, additional, Cook, Gordon, additional, Chantry, Andrew, additional, Jenner, Matthew, additional, Buadi, Francis, additional, Berryman, Robert, additional, and Janakiram, Murali, additional
Published: 2019
Full Text: View/download PDF

120. Health-related quality of life in multiple myeloma patients with first relapse treated with Carfilzomib-based re-induction and salvage autologous stem cell transplantation : data from a Nordic phase II trial

Author: Eshoj, Henrik Rode, Nielsen, Lene Kongsgaard, Schjesvold, Fredrik, Abildgaard, Niels, Nahi, Hareth, Andersen, Niels Frost, Vangsted, Annette Juul, Helleberg, Carsten, Frølund, Ulf Christian, Axelsson, Per, Stromberg, Olga, Blimark, Cecilie, Carlson, Kristina, Waage, Anders, Remes, Kari, Peceliunas, Valdas, Guldbrandsen, Nina, Hansson, Markus, Gregersen, Henrik, Eshoj, Henrik Rode, Nielsen, Lene Kongsgaard, Schjesvold, Fredrik, Abildgaard, Niels, Nahi, Hareth, Andersen, Niels Frost, Vangsted, Annette Juul, Helleberg, Carsten, Frølund, Ulf Christian, Axelsson, Per, Stromberg, Olga, Blimark, Cecilie, Carlson, Kristina, Waage, Anders, Remes, Kari, Peceliunas, Valdas, Guldbrandsen, Nina, Hansson, Markus, and Gregersen, Henrik
Abstract: Meeting Abstract: 2048
Published: 2018
Full Text: View/download PDF

121. Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma

Author: Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frolund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf-Henrik, Nahi, Hareth, Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frolund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf-Henrik, and Nahi, Hareth
Abstract: Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single-agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with RRMM who responded to first-line Len+Dex in an observational study (NCT01430546) received up to 24 cycles of either Len (25mg/day) or Len+Dex (25mg/day and 40mg/week) as prolonged treatment in a subsequent phase 2 clinical trial (NCT01450215). In the observational study (N = 133), median time to response was 1.7 (range 0.6-9.6) months. A complete response to all treatments received in both studies was observed in 11% of patients; very good partial response and partial response rates were 31% and 38%, respectively. Corresponding response rates in the subgroup of patients who did not enter the phase 2 trial (n = 71) were 3%, 18%, and 39%, respectively. Rates of disease progression at 2years in the phase 2 trial were 47% versus 31% for Len versus Len+Dex (P = 0.14). After 36months median follow-up in surviving patients, median time to progression was not reached with Len+Dex and was 24.9months (95% confidence interval 12.5-not calculable, P amp;lt; 0.001) with Len. Three-year OS among the total observational study population was 61% (95% CI, 52-69%). The corresponding rate among patients who entered the phase 2 clinical trial was 73% (95% CI, 60-83%) and was significantly lower among those patients who achieved PR but did not proceed into the phase 2 trial (55%; P = 0.01). In the phase 2 trial, OS was 73% in both treatment arms (P = 0.70). Neutropenia and thrombocytopenia were more common with prolonged (phase 2 trial) versus short-term (observational study) Len administration but remained manageable. Prolonged treatment with Len with or without Dex provides sustained, clinically relevant responses and demonstrates an acceptable safety profile., Funding Agencies|Celgene Corporation; Swedish Cancer Society
Published: 2018
Full Text: View/download PDF

122. Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma

Author: Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frølund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf-Henrik, Nahi, Hareth, Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frølund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf-Henrik, and Nahi, Hareth
Abstract: Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single-agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with RRMM who responded to first-line Len+Dex in an observational study (NCT01430546) received up to 24 cycles of either Len (25 mg/day) or Len+Dex (25 mg/day and 40 mg/week) as prolonged treatment in a subsequent phase 2 clinical trial (NCT01450215). In the observational study (N = 133), median time to response was 1.7 (range 0.6-9.6) months. A complete response to all treatments received in both studies was observed in 11% of patients; very good partial response and partial response rates were 31% and 38%, respectively. Corresponding response rates in the subgroup of patients who did not enter the phase 2 trial (n = 71) were 3%, 18%, and 39%, respectively. Rates of disease progression at 2 years in the phase 2 trial were 47% versus 31% for Len versus Len+Dex (P = 0.14). After 36 months median follow-up in surviving patients, median time to progression was not reached with Len+Dex and was 24.9 months (95% confidence interval 12.5-not calculable, P < 0.001) with Len. Three-year OS among the total observational study population was 61% (95% CI, 52-69%). The corresponding rate among patients who entered the phase 2 clinical trial was 73% (95% CI, 60-83%) and was significantly lower among those patients who achieved ≥PR but did not proceed into the phase 2 trial (55%; P = 0.01). In the phase 2 trial, OS was 73% in both treatment arms (P = 0.70). Neutropenia and thrombocytopenia were more common with prolonged (phase 2 trial) versus short-term (observational study) Len administration but remained manageable. Prolonged treatment with Len with or without Dex provides sustained, clinically relevant responses and demonstrates an acceptable safety profile.
Published: 2018

123. Quality of life with melphalan/prednisone plus either thalidomide (MPT-T) or lenalidomide (MPR-R) in non-transplant eligible newly diagnosed multiple myeloma:results of the HOVON87/NMSG18 study

Author: Stege, Claudia A.M., Kongsgaard Nielsen, Lene, Witte, Birgit, van der Holt, Bronno, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard, Levin, Mark-David, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette, Deenik, Wendy, Gruber, Astrid, Coenen, Juleon, Plesner, Torben, Klein, Saskia, Tanis, Bea, Szatkowski, Damian L., Brouwer, Rolf, Westerman, Matthijs, Leys, Rineke, Sinnige, Harm, Haukås, Einar, van der Hem, Klaas, Durian, Marc, Mattijssen, Vera, Gimsing, Peter, van de Donk, Niels, Stevens-Kroef, Marian, Sonneveld, Pieter, Waage, Anders, Zweegman, Sonja, and Abildgaard , Niels
Published: 2017

124. Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial

Author: Zweegman, Sonja, Sonneveld, Pieter, van der Holt, Bruno, Waage, Anders, Klein, Saskia, Abildgaard , Niels, Hieu Do, Trung, Hansson, Markus, Schjesvold, Fredrik H., Levin, Mark-David, Stege, Claudia A.M., Leijs, Maria Berhardina, Szatkowski, Damian L., Broyl, A, Axelsson, Per, Knut-Bojanovska, Dorota, van der Spek, Ellen van der Spek, Svirskaite, Asta S, Cunha, Sonia, and Haukås, Einar
Published: 2017

125. An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Author: Dimopoulos, Meletios Grosicki, Sebastian Jedrzejczak, Wieslaw and Nahi, Hareth Gruber, Astrid Hansson, Markus Byrne, Catriona Labotka, Richard Teng, Zhaoyang Yang, Huyuan and Grzasko, Norbert Kumar, Shaji
Published: 2017

126. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine

Author: Mellqvist, Ulf-Henrik, Hansson, Markus, Brune, Mats, Dahlgren, Claes, Hermodsson, Svante, and Hellstrand, Kristoffer
Published: 2000
Full Text: View/download PDF

127. Adjuvant histamine in cancer immunotherapy

Author: Hellstrand, Kristoffer, Hansson, Markus, and Hermodsson, Svante
Published: 2000
Full Text: View/download PDF

128. Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Author: Zweegman, Sonja, primary, Schjesvold, Fredrik H., additional, van der Holt, Bronno, additional, Levin, Mark-David, additional, Stege, Claudia A.M., additional, Waage, Anders, additional, Leijs, Maria B.L., additional, Klein, Saskia K., additional, Szatkowski, Damian L., additional, Axelsson, Per, additional, Hieu Do, Trung, additional, Knut-Bojanovska, Dorota, additional, van der Spek, Ellen, additional, Svirskaite, Asta, additional, Poddighe, Pino, additional, Stevens-Kroef, Marian, additional, Hansson, Markus, additional, van de Donk, Niels WCJ, additional, Haukas, Einar, additional, Sonneveld, Pieter, additional, and Abildgaard, Niels, additional
Published: 2018
Full Text: View/download PDF

129. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Author: Schmidt, Amand F, primary, Holmes, Michael V, additional, Preiss, David, additional, Swerdlow, Daniel, additional, Denaxas, Spiros, additional, Fatemifar, Ghazaleh, additional, Faraway, Rupert, additional, Finan, Chris, additional, Lumbers, Tom, additional, Henry, Albert, additional, Valentine, Dennis, additional, Fairhurst-Hunter, Zammy, additional, Hartwig, Fernando Pires, additional, Horta, Bernardo Lessa, additional, Hypponen, Elina, additional, Power, Christine, additional, Moldovan, Max, additional, van Iperen, Erik, additional, Hovingh, Kees, additional, Demuth, Ilja, additional, Norman, Kristina, additional, Steinhagen-Thiessen, Elisabeth, additional, Demuth, Juri, additional, Bertram, Lars, additional, Lill, Christina M, additional, Coassin, Stefan, additional, Willeit, Johann, additional, Kiechl, Stefan, additional, Willeit, Karin, additional, Mason, Dan, additional, Wright, John, additional, Morris, Richard, additional, Wanamethee, Goya, additional, Whincup, Peter, additional, Ben-Shlomo, Yoav, additional, McLachlan, Stela, additional, Price, Jackie F., additional, Kivimaki, Mika, additional, Welch, Catherine, additional, Sanchez-Galvez, Adelaida, additional, Marques-Vidal, Pedro, additional, Nicolaides, Andrew, additional, Panayiotou, Andrie G., additional, Onland-Moret, N. Charlotte, additional, van der Schouw, Yvonne T., additional, Matullo, Giuseppe, additional, Fiorito, Giovanni, additional, Guarrera, Simonetta, additional, Sacerdote, Carlotta, additional, Wareham, Nicholas J, additional, Langenberg, Claudia, additional, Scott, Robert A, additional, Luan, Jian’an, additional, Bobak, Martin, additional, Malyutina, Sofia, additional, Pajak, Andrzej, additional, Kubinova, Ruzena, additional, Tamosiunas, Abdonas, additional, Pikhart, Hynek, additional, Grarup, Niels, additional, Pedersen, Oluf, additional, Hansen, Torben, additional, Linneberg, Allan, additional, Jess, Tine, additional, Cooper, Jackie, additional, Humphries, Steve E, additional, Brilliant, Murray, additional, Kitchner, Terrie, additional, Hakonarson, Hakon, additional, Carrell, David S., additional, McCarty, Catherine A., additional, Lester, Kirchner H, additional, Larson, Eric B., additional, Crosslin, David R., additional, Andrade, Mariza de, additional, Roden, Dan M, additional, Denny, Joshua C, additional, Carty, Cara, additional, Hancock, Stephen, additional, Attia, John, additional, Holliday, Elizabeth, additional, Scott, Rodney, additional, Schofield, Peter, additional, O’Donnell, Martin, additional, Yusuf, Salim, additional, Chong, Michael, additional, Pare, Guillaume, additional, van der Harst, Pim, additional, Said, M. Abdullah, additional, Eppinga, Ruben N., additional, Verweij, Niek, additional, Snieder, Harold, additional, Christen, Tim, additional, Mook-Kanamori, D.O., additional, Gustafsson, Stefan, additional, Lind, Lars, additional, Ingelsson, Erik, additional, Pazoki, Raha, additional, Franco, Oscar, additional, Hofman, Albert, additional, Uitterlinden, Andre, additional, Dehghan, Abbas, additional, Teumer, Alexander, additional, Baumeister, Sebastian, additional, Dörr, Marcus, additional, Lerch, Markus M., additional, Völker, Uwe, additional, Völzke, Henry, additional, Ward, Joey, additional, Pell, Jill P, additional, Meade, Tom, additional, Christophersen, Ingrid E., additional, Maitland-van der Zee, Anke H., additional, Baranova, Ekaterina V., additional, Young, Robin, additional, Ford, Ian, additional, Campbell, Archie, additional, Padmanabhan, Sandosh, additional, Bots, Michiel L, additional, Grobbee, Diederick E., additional, Froguel, Philippe, additional, Thuillier, Dorothée, additional, Roussel, Ronan, additional, Bonnefond, Amelie, additional, Cariou, Bertrand, additional, Smart, Melissa, additional, Bao, Yanchun, additional, Kumari, Meena, additional, Mahajan, Anubha, additional, Hopewell, Jemma C., additional, Seshadri, Sudha, additional, Dale, Caroline, additional, Costa, Rui Providencia E, additional, Ridker, Paul M, additional, Chasman, Daniel I., additional, Reiner, Alex P., additional, Ritchie, Marylyn D, additional, Lange, Leslie A, additional, Cornish, Alex J., additional, Dobbins, Sara E., additional, Hemminki, Kari, additional, Kinnersley, Ben, additional, Sanson, Marc, additional, Labreche, Karim, additional, Simon, Matthias, additional, Bondy, Melissa, additional, Law, Philip, additional, Speedy, Helen, additional, Allan, James, additional, Li, Ni, additional, Went, Molly, additional, Weinhold, Niels, additional, Morgan, Gareth, additional, Sonneveld, Pieter, additional, Nilsson, Björn, additional, Goldschmidt, Hartmut, additional, Sud, Amit, additional, Engert, Andreas, additional, Hansson, Markus, additional, Hemingway, Harry, additional, Asselbergs, Folkert W, additional, Patel, Riyaz S, additional, Keating, Brendan J, additional, Sattar, Naveed, additional, Houlston, Richard, additional, Casas, Juan P, additional, and Hingorani, Aroon D, additional
Published: 2018
Full Text: View/download PDF

130. The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression

Author: Ali, Mina, primary, Ajore, Ram, additional, Wihlborg, Anna-Karin, additional, Niroula, Abhishek, additional, Swaminathan, Bhairavi, additional, Johnsson, Ellinor, additional, Stephens, Owen W, additional, Morgan, Gareth, additional, Meissner, Tobias, additional, Turesson, Ingemar, additional, Goldschmidt, Hartmut, additional, Mellqvist, Ulf-Henrik, additional, Gullberg, Urban, additional, Hansson, Markus, additional, Hemminki, Kari, additional, Nahi, Hareth, additional, Waage, Anders, additional, Weinhold, Niels, additional, and Nilsson, Björn, additional
Published: 2018
Full Text: View/download PDF

131. Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma

Author: Lund, Johan, primary, Gruber, Astrid, additional, Lauri, Birgitta, additional, Duru, Adil Doganay, additional, Blimark, Cecilie, additional, Swedin, Agneta, additional, Hansson, Markus, additional, Forsberg, Karin, additional, Ahlberg, Lucia, additional, Carlsson, Conny, additional, Waage, Anders, additional, Gimsing, Peter, additional, Vangsted, Annette Juul, additional, Frølund, Ulf, additional, Holmberg, Erik, additional, Gahrton, Gösta, additional, Alici, Evren, additional, Hardling, Mats, additional, Mellqvist, Ulf-Henrik, additional, and Nahi, Hareth, additional
Published: 2018
Full Text: View/download PDF

132. Additional file 1: of Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis

Author: Ă Sa Johansson, Ohlsson, Sophie, Ă Sa Pettersson, Bengtsson, Anders, Selga, Daina, Hansson, Markus, and Hellmark, Thomas
Abstract: Gating strategies. (DOCX 188 kb)
Published: 2016
Full Text: View/download PDF

133. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Author: Dimopoulos, Meletios A Palumbo, Antonio Corradini, Paolo Cavo, Michele Delforge, Michel Di Raimondo, Francesco Weisel, Katja C Oriol, Albert Hansson, Markus Vacca, Angelo others
Subjects: Health Sciences, Επιστήμες Υγείας
Published: 2016

134. An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Author: Dimopoulos, Meletios, primary, Grosicki, Sebastian, additional, Jędrzejczak, Wiesław, additional, Nahi, Hareth, additional, Gruber, Astrid, additional, Hansson, Markus, additional, Byrne, Catriona, additional, Labotka, Richard, additional, Teng, Zhaoyang, additional, Yang, Huyuan, additional, Grzasko, Norbert, additional, and Kumar, Shaji, additional
Published: 2017
Full Text: View/download PDF

135. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Author: Mateos, María-Victoria, primary, Masszi, Tamas, additional, Grzasko, Norbert, additional, Hansson, Markus, additional, Sandhu, Irwindeep, additional, Pour, Ludek, additional, Viterbo, Luísa, additional, Jackson, Sharon R., additional, Stoppa, Anne-Marie, additional, Gimsing, Peter, additional, Hamadani, Mehdi, additional, Borsaru, Gabriela, additional, Berg, Deborah, additional, Lin, Jianchang, additional, Di Bacco, Alessandra, additional, van de Velde, Helgi, additional, Richardson, Paul G., additional, and Moreau, Philippe, additional
Published: 2017
Full Text: View/download PDF

136. Identification of sequence variants influencing immunoglobulin levels

Author: Jonsson, Stefan, primary, Sveinbjornsson, Gardar, additional, de Lapuente Portilla, Aitzkoa Lopez, additional, Swaminathan, Bhairavi, additional, Plomp, Rosina, additional, Dekkers, Gillian, additional, Ajore, Ram, additional, Ali, Mina, additional, Bentlage, Arthur E H, additional, Elmér, Evelina, additional, Eyjolfsson, Gudmundur I, additional, Gudjonsson, Sigurjon A, additional, Gullberg, Urban, additional, Gylfason, Arnaldur, additional, Halldorsson, Bjarni V, additional, Hansson, Markus, additional, Holm, Hilma, additional, Johansson, Åsa, additional, Johnsson, Ellinor, additional, Jonasdottir, Aslaug, additional, Ludviksson, Bjorn R, additional, Oddsson, Asmundur, additional, Olafsson, Isleifur, additional, Olafsson, Sigurgeir, additional, Sigurdardottir, Olof, additional, Sigurdsson, Asgeir, additional, Stefansdottir, Lilja, additional, Masson, Gisli, additional, Sulem, Patrick, additional, Wuhrer, Manfred, additional, Wihlborg, Anna-Karin, additional, Thorleifsson, Gudmar, additional, Gudbjartsson, Daniel F, additional, Thorsteinsdottir, Unnur, additional, Vidarsson, Gestur, additional, Jonsdottir, Ingileif, additional, Nilsson, Björn, additional, and Stefansson, Kari, additional
Published: 2017
Full Text: View/download PDF

137. NOX2-dependent immunosuppression in chronic myelomonocytic leukemia

Author: Aurelius, Johan, primary, Hallner, Alexander, additional, Werlenius, Olle, additional, Riise, Rebecca, additional, Moüllgård, Lars, additional, Brune, Mats, additional, Hansson, Markus, additional, Martner, Anna, additional, Thorén, Fredrik B, additional, and Hellstrand, Kristoffer, additional
Published: 2017
Full Text: View/download PDF

138. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma

Author: Wichert, Stina, primary, Juliusson, Gunnar, additional, Johansson, Åsa, additional, Sonesson, Elisabeth, additional, Teige, Ingrid, additional, Wickenberg, Anna Teige, additional, Frendeus, Björn, additional, Korsgren, Magnus, additional, and Hansson, Markus, additional
Published: 2017
Full Text: View/download PDF

139. Analysis of patients with refractory or relapsed and refractory multiple myeloma and renal impairment treated with pomalidomide+ low-dose dexamethasone in the phase 3B STRATUS trial (MM-010)

Author: Weisel, Katja Dimopoulos, Meletios A Palumbo, Antonio Corradini, Paolo Cavo, Michele Delforge, Michel Ocio, Enrique M Vacca, Angelo Hansson, Markus Blanchard, Maria others
Subjects: Health Sciences, Επιστήμες Υγείας
Published: 2015

140. An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Author: Dimopoulos, Meletios A. Palumbo, Antonio Corradini, Paolo and Cavo, Michele Delforge, Michel Weisel, Katja C. Ocio, Enrique M. Di Raimondo, Francesco Hansson, Markus Simcock, Mathew Miller, Neil Slaughter, Ana Peluso, Teresa and Sternas, Lars Zaki, Mohamed H. Moreau, Philippe
Published: 2015

141. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

Author: Kuiper, Rowan, Zweegman, Sonja, van Duin, Mark, van Vliet, Martin H., van Beers, Erik H., Dumee, Belinda, Vermeulen, Michael, Koenders, Jasper, van der Holt, Bronno, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette W. G., Beverloo, H. Berna, Stevens-Kroef, Marian, Levin, Mark-David, Broijl, Annemiek, Waage, Anders, and Sonneveld, Pieter
Abstract: The standard prognostic marker for multiple myeloma (MM) patients is the revised International Staging System (R-ISS). However, there is room for improvement in guiding treatment. This applies particularly to older patients, in whom the benefit/risk ratio is reduced because of comorbidities and subsequent side effects. We hypothesized that adding gene-expression data to R-ISS would generate a stronger marker. This was tested by combining R-ISS with the SKY92 classifier (SKY-RISS). The HOVON-87/NMSG-18 trial (EudraCT: 2007-004007-34) compared melphalan-prednisone-thalidomide followed by thalidomide maintenance (MPT-T) with melphalan-prednisone-lenalidomide followed by lenalidomide maintenance (MPR-R). From this trial, 168 patients with available R-ISS status and gene-expression profiles were analyzed. R-ISS stages I, II, and III were assigned to 8%, 75%, and 7% of patients, respectively (3-year overall survival [OS] rates: 80%, 65%, 33%, P = 8 × 10−3). Using the SKY92 classifier, 13% of patients were high risk (HR) (3-year OS rates: standard risk [SR], 70%; HR, 28%; P < .001). Combining SKY92 with R-ISS resulted in 3 risk groups: SKY-RISS I (SKY-SR + R-ISS-I; 15%), SKY-RISS III (SKY-HR + R-ISS-II/III; 11%), and SKY-RISS II (all other patients; 74%). The 3-year OS rates for SKY-RISS I, II, and III are 88%, 66%, and 26%, respectively (P = 6 × 10−7). The SKY-RISS model was validated in older patients from the CoMMpass dataset. Moreover, SKY-RISS demonstrated predictive potential: HR patients appeared to benefit from MPR-R over MPT-T (median OS, 55 and 14 months, respectively). Combined, SKY92 and R-ISS classify patients more accurately. Additionally, benefit was observed for MPR-R over MPT-T in SKY92-RISS HR patients only.
Published: 2020
Full Text: View/download PDF

142. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Author: Cavo, Michele, Gay, Francesca, Beksac, Meral, Pantani, Lucia, Petrucci, Maria Teresa, Dimopoulos, Meletios A, Dozza, Luca, van der Holt, Bronno, Zweegman, Sonja, Oliva, Stefania, van der Velden, Vincent H J, Zamagni, Elena, Palumbo, Giuseppe A, Patriarca, Francesca, Montefusco, Vittorio, Galli, Monica, Maisnar, Vladimir, Gamberi, Barbara, Hansson, Markus, Belotti, Angelo, Pour, Ludek, Ypma, Paula, Grasso, Mariella, Croockewit, Alexsandra, Ballanti, Stelvio, Offidani, Massimo, Vincelli, Iolanda D, Zambello, Renato, Liberati, Anna Marina, Andersen, Niels Frost, Broijl, Annemiek, Troia, Rossella, Pascarella, Anna, Benevolo, Giulia, Levin, Mark-David, Bos, Gerard, Ludwig, Heinz, Aquino, Sara, Morelli, Anna Maria, Wu, Ka Lung, Boersma, Rinske, Hajek, Roman, Durian, Marc, von dem Borne, Peter A, Caravita di Toritto, Tommaso, Zander, Thilo, Driessen, Christoph, Specchia, Giorgina, Waage, Anders, Gimsing, Peter, Mellqvist, Ulf-Henrik, van Marwijk Kooy, Marinus, Minnema, Monique, Mandigers, Caroline, Cafro, Anna Maria, Palmas, Angelo, Carvalho, Susanna, Spencer, Andrew, Boccadoro, Mario, and Sonneveld, Pieter
Abstract: The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared autologous HSCT with bortezomib–melphalan–prednisone (VMP) as intensification therapy, and bortezomib–lenalidomide–dexamethasone (VRD) consolidation therapy with no consolidation.
Published: 2020
Full Text: View/download PDF

143. Search for multiple myeloma risk factors using Mendelian randomization

Author: Went, Molly, Cornish, Alex J., Law, Philip J., Kinnersley, Ben, van Duin, Mark, Weinhold, Niels, Försti, Asta, Hansson, Markus, Sonneveld, Pieter, Goldschmidt, Hartmut, Morgan, Gareth J., Hemminki, Kari, Nilsson, Björn, Kaiser, Martin, and Houlston, Richard S.
Abstract: The etiology of multiple myeloma (MM) is poorly understood. Summary data from genome-wide association studies (GWASs) of multiple phenotypes can be exploited in a Mendelian randomization (MR) phenome-wide association study (PheWAS) to search for factors influencing MM risk. We performed an MR-PheWAS analyzing 249 phenotypes, proxied by 10 225 genetic variants, and summary genetic data from a GWAS of 7717 MM cases and 29 304 controls. Odds ratios (ORs) per 1 standard deviation increase in each phenotype were estimated under an inverse variance weighted random effects model. A Bonferroni-corrected threshold of P = 2 × 10−4 was considered significant, whereas P < .05 was considered suggestive of an association. Although no significant associations with MM risk were observed among the 249 phenotypes, 28 phenotypes showed evidence suggestive of association, including increased levels of serum vitamin B6 and blood carnitine (P = 1.1 × 10−3) with greater MM risk and ω-3 fatty acids (P = 5.4 × 10−4) with reduced MM risk. A suggestive association between increased telomere length and reduced MM risk was also noted; however, this association was primarily driven by the previously identified risk variant rs10936599 at 3q26 (TERC). Although not statistically significant, increased body mass index was associated with increased risk (OR, 1.10; 95% confidence interval, 0.99-1.22), supporting findings from a previous meta-analysis of prospective observational studies. Our study did not provide evidence supporting any modifiable factors examined as having a major influence on MM risk; however, it provides insight into factors for which the evidence has previously been mixed.
Published: 2020
Full Text: View/download PDF

144. Robust isolation of malignant plasma cells in multiple myeloma

Author: Frigyesi, Ildikó, Adolfsson, Jörgen, Ali, Mina, Kronborg Christophersen, Mikael, Johnsson, Ellinor, Turesson, Ingemar, Gullberg, Urban, Hansson, Markus, and Nilsson, Björn
Published: 2014
Full Text: View/download PDF

145. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Author: Dimopoulos, Meletios A, Palumbo, Antonio, Corradini, Paolo, Cavo, Michele, Delforge, Michel, Di Raimondo, Francesco, Weisel, Katja C, Oriol, Albert, Hansson, Markus, Vacca, Angelo, Blanchard, María Jesús, Goldschmidt, Hartmut, Doyen, Chantal, Kaiser, Martin, Petrini, Mario, Anttila, Pekka, Cafro, Anna Maria, Raymakers, Reinier, San-Miguel, Jesus, de Arriba, Felipe, Knop, Stefan, Röllig, Christoph, Ocio, Enrique M, Morgan, Gareth, Miller, Neil, Simcock, Mathew, Peluso, Teresa, Herring, Jennifer, Sternas, Lars, Zaki, Mohamed H, Moreau, Philippe, Dimopoulos, Meletios A, Palumbo, Antonio, Corradini, Paolo, Cavo, Michele, Delforge, Michel, Di Raimondo, Francesco, Weisel, Katja C, Oriol, Albert, Hansson, Markus, Vacca, Angelo, Blanchard, María Jesús, Goldschmidt, Hartmut, Doyen, Chantal, Kaiser, Martin, Petrini, Mario, Anttila, Pekka, Cafro, Anna Maria, Raymakers, Reinier, San-Miguel, Jesus, de Arriba, Felipe, Knop, Stefan, Röllig, Christoph, Ocio, Enrique M, Morgan, Gareth, Miller, Neil, Simcock, Mathew, Peluso, Teresa, Herring, Jennifer, Sternas, Lars, Zaki, Mohamed H, and Moreau, Philippe
Published: 2016

146. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma

Author: Mitchell, Jonathan S., Li, Ni, Weinhold, Niels, Försti, Asta, Ali, Mina, van Duin, Mark, Thorleifsson, Gudmar, Johnson, David C., Chen, Bowang, Halvarsson, Britt-Marie, Gudbjartsson, Daniel F., Kuiper, Rowan, Stephens, Owen W., Bertsch, Uta, Broderick, Peter, Campo, Chiara, Einsele, Hermann, Gregory, Walter A., Gullberg, Urban, Henrion, Marc, Hillengass, Jens, Hoffmann, Per, Jackson, Graham H., Johnsson, Ellinor, Jöud, Magnus, Kristinsson, Sigurjdur Y., Lenhoff, Stig, Lenive, Oleg, Mellqvist, Ulf-Henrik, Migliorini, Gabriele, Nahi, Hareth, Nelander, Sven, Nickel, Jolanta, Nöthen, Markus M., Rafnar, Thorunn, Ross, Fiona M., da Silva Filho, Miguel Inacio, Swaminathan, Bhairavi, Thomsen, Hauke, Turesson, Ingemar, Vangsted, Annette, Vogel, Ulla, Waage, Anders, Walker, Brian A., Wihlborg, Anna-Karin, Broyl, Annemiek, Davies, Faith E., Thorsteinsdottir, Unnur, Langer, Christian, Hansson, Markus, Kaiser, Martin, Sonneveld, Pieter, Stefansson, Kari, Morgan, Gareth J., Goldschmidt, Hartmut, Hemminki, Kari, Nilsson, Björn, Houlston, Richard S., Mitchell, Jonathan S., Li, Ni, Weinhold, Niels, Försti, Asta, Ali, Mina, van Duin, Mark, Thorleifsson, Gudmar, Johnson, David C., Chen, Bowang, Halvarsson, Britt-Marie, Gudbjartsson, Daniel F., Kuiper, Rowan, Stephens, Owen W., Bertsch, Uta, Broderick, Peter, Campo, Chiara, Einsele, Hermann, Gregory, Walter A., Gullberg, Urban, Henrion, Marc, Hillengass, Jens, Hoffmann, Per, Jackson, Graham H., Johnsson, Ellinor, Jöud, Magnus, Kristinsson, Sigurjdur Y., Lenhoff, Stig, Lenive, Oleg, Mellqvist, Ulf-Henrik, Migliorini, Gabriele, Nahi, Hareth, Nelander, Sven, Nickel, Jolanta, Nöthen, Markus M., Rafnar, Thorunn, Ross, Fiona M., da Silva Filho, Miguel Inacio, Swaminathan, Bhairavi, Thomsen, Hauke, Turesson, Ingemar, Vangsted, Annette, Vogel, Ulla, Waage, Anders, Walker, Brian A., Wihlborg, Anna-Karin, Broyl, Annemiek, Davies, Faith E., Thorsteinsdottir, Unnur, Langer, Christian, Hansson, Markus, Kaiser, Martin, Sonneveld, Pieter, Stefansson, Kari, Morgan, Gareth J., Goldschmidt, Hartmut, Hemminki, Kari, Nilsson, Björn, and Houlston, Richard S.
Abstract: Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-wide association studies have transformed our understanding of MM predisposition, but individual studies have had limited power to discover risk loci. Here we perform a meta-analysis of these GWAS, add a new GWAS and perform replication analyses resulting in 9,866 cases and 239,188 controls. We confirm all nine known risk loci and discover eight new loci at 6p22.3 (rs34229995, P = 1.31 x 10(-8)), 6q21 (rs9372120, P = 9.09 x 10(-15)), 7q36.1 (rs7781265, P = 9.71 x 10(-9)), 8q24.21 (rs1948915, P = 4.20 x 10(-11)), 9p21.3 (rs2811710, P = 1.72 x 10(-13)), 10p12.1 (rs2790457, P = 1.77 x 10(-8)), 16q23.1 (rs7193541, P = 5.00 x 10(-12)) and 20q13.13 (rs6066835, P = 1.36 x 10(-13)), which localize in or near to JARID2, ATG5, SMARCD3, CCAT1, CDKN2A, WAC, RFWD3 and PREX1. These findings provide additional support for a polygenic model of MM and insight into the biological basis of tumour development.
Published: 2016
Full Text: View/download PDF

147. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUSTM (MM-010): a phase 3b study in refractory multiple myeloma.

Author: UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Dimopoulos, Meletios A, Palumbo, Antonio, Corradini, Paolo, Cavo, Michele, Delforge, Michel, Di Raimondo, Francesco, Weisel, Katja C, Oriol, Albert, Hansson, Markus, Vacca, Angelo, Blanchard, Maria Jesus, Goldschmidt, Hartmut, Doyen, Chantal, Kaiser, Martin, Petrini, Mario, Anttila, Pekka, Cafro, Anna Maria, Raymakers, Reinier, San Miguel, Jesus, de Arriba, Felipe, Knop, Stefan, Röllig, Christoph, Ocio, Enrique M, Morgan, Gareth, Miller, Neil, Simcock, Mathew, Peluso, Teresa, Herring, Jennifer, Sternas, Lars, Zaki, Mohamed, Moreau, Philippe, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Dimopoulos, Meletios A, Palumbo, Antonio, Corradini, Paolo, Cavo, Michele, Delforge, Michel, Di Raimondo, Francesco, Weisel, Katja C, Oriol, Albert, Hansson, Markus, Vacca, Angelo, Blanchard, Maria Jesus, Goldschmidt, Hartmut, Doyen, Chantal, Kaiser, Martin, Petrini, Mario, Anttila, Pekka, Cafro, Anna Maria, Raymakers, Reinier, San Miguel, Jesus, de Arriba, Felipe, Knop, Stefan, Röllig, Christoph, Ocio, Enrique M, Morgan, Gareth, Miller, Neil, Simcock, Mathew, Peluso, Teresa, Herring, Jennifer, Sternas, Lars, Zaki, Mohamed, and Moreau, Philippe
Abstract: Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS(TM) study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients with RRMM. Patients who failed treatment with bortezomib and lenalidomide and had adequate prior alkylator therapy were eligible. Pomalidomide 4 mg was given on days 1-21 of 28-day cycles with low-dose dexamethasone 40 mg (20 mg for pts aged > 75 years) on days 1, 8, 15, and 22 until progressive disease or unacceptable toxicity. Safety was the primary end point; secondary end points included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Among 682 patients enrolled, median age was 66 years and median time since diagnosis was 5.3 years. Median number of prior regimens was 5. Most patients were refractory to both lenalidomide and bortezomib (80.2%). Median follow-up was 16.8 months; median duration of treatment was 4.9 months. Most frequent grade 3/4 treatment-emergent adverse events were hematologic (neutropenia [49.7%], anemia [33.0%], and thrombocytopenia [24.1%]). Most common grade 3/4 nonhematologic toxicities were pneumonia (10.9%) and fatigue (5.9%). Grade 3/4 venous thromboembolism and peripheral neuropathy were rare (1.6% each). The ORR was 32.6%, and the median DOR was 7.4 months. Median PFS and OS were 4.6 months and 11.9 months, respectively. We present the largest trial to date evaluating pomalidomide plus low-dose dexamethasone in patients with RRMM, further confirming that this regimen offers clinically meaningful benefit and is generally well-tolerated. www.Clinicaltrials.gov identifier NCT01712789.
Published: 2016

148. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma

Author: Mitchell, Jonathan S, Li, Ni, Weinhold, Niels, Försti, Asta, Ali, Mina, van Duin, Mark, Thorleifsson, Gudmar, Johnson, David C, Chen, Bowang, Halvarsson, Britt-Marie, Gudbjartsson, Daniel F, Kuiper, Rowan, Stephens, Owen W, Bertsch, Uta, Broderick, Peter, Campo, Chiara, Einsele, Hermann, Gregory, Walter A, Gullberg, Urban, Henrion, Marc, Hillengass, Jens, Hoffmann, Per, Jackson, Graham H, Johnsson, Ellinor, Jöud, Magnus, Kristinsson, Sigurður Y, Lenhoff, Stig, Lenive, Oleg, Mellqvist, Ulf-Henrik, Migliorini, Gabriele, Nahi, Hareth, Nelander, Sven, Nickel, Jolanta, Nöthen, Markus M, Rafnar, Thorunn, Ross, Fiona M, da Silva Filho, Miguel Inacio, Swaminathan, Bhairavi, Thomsen, Hauke, Turesson, Ingemar, Vangsted, Annette, Vogel, Ulla, Waage, Anders, Walker, Brian A, Wihlborg, Anna-Karin, Broyl, Annemiek, Davies, Faith E, Thorsteinsdottir, Unnur, Langer, Christian, Hansson, Markus, Kaiser, Martin, Sonneveld, Pieter, Stefansson, Kari, Morgan, Gareth J, Goldschmidt, Hartmut, Hemminki, Kari, Nilsson, Björn, Houlston, Richard S, Mitchell, Jonathan S, Li, Ni, Weinhold, Niels, Försti, Asta, Ali, Mina, van Duin, Mark, Thorleifsson, Gudmar, Johnson, David C, Chen, Bowang, Halvarsson, Britt-Marie, Gudbjartsson, Daniel F, Kuiper, Rowan, Stephens, Owen W, Bertsch, Uta, Broderick, Peter, Campo, Chiara, Einsele, Hermann, Gregory, Walter A, Gullberg, Urban, Henrion, Marc, Hillengass, Jens, Hoffmann, Per, Jackson, Graham H, Johnsson, Ellinor, Jöud, Magnus, Kristinsson, Sigurður Y, Lenhoff, Stig, Lenive, Oleg, Mellqvist, Ulf-Henrik, Migliorini, Gabriele, Nahi, Hareth, Nelander, Sven, Nickel, Jolanta, Nöthen, Markus M, Rafnar, Thorunn, Ross, Fiona M, da Silva Filho, Miguel Inacio, Swaminathan, Bhairavi, Thomsen, Hauke, Turesson, Ingemar, Vangsted, Annette, Vogel, Ulla, Waage, Anders, Walker, Brian A, Wihlborg, Anna-Karin, Broyl, Annemiek, Davies, Faith E, Thorsteinsdottir, Unnur, Langer, Christian, Hansson, Markus, Kaiser, Martin, Sonneveld, Pieter, Stefansson, Kari, Morgan, Gareth J, Goldschmidt, Hartmut, Hemminki, Kari, Nilsson, Björn, and Houlston, Richard S
Abstract: Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-wide association studies have transformed our understanding of MM predisposition, but individual studies have had limited power to discover risk loci. Here we perform a meta-analysis of these GWAS, add a new GWAS and perform replication analyses resulting in 9,866 cases and 239,188 controls. We confirm all nine known risk loci and discover eight new loci at 6p22.3 (rs34229995, P=1.31 × 10(-8)), 6q21 (rs9372120, P=9.09 × 10(-15)), 7q36.1 (rs7781265, P=9.71 × 10(-9)), 8q24.21 (rs1948915, P=4.20 × 10(-11)), 9p21.3 (rs2811710, P=1.72 × 10(-13)), 10p12.1 (rs2790457, P=1.77 × 10(-8)), 16q23.1 (rs7193541, P=5.00 × 10(-12)) and 20q13.13 (rs6066835, P=1.36 × 10(-13)), which localize in or near to JARID2, ATG5, SMARCD3, CCAT1, CDKN2A, WAC, RFWD3 and PREX1. These findings provide additional support for a polygenic model of MM and insight into the biological basis of tumour development.
Published: 2016

149. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Author: Celgene, Dimopoulos, Meletios A., Palumbo, Antonio, Corradini, Paolo, Cavo, Michele, Delforge, Michel, Di Raimondo, Francesco, Weisel, Katja C., Oriol, Albert, Hansson, Markus, Vacca, Angelo, Blanchard, María Jesús, Goldschmidt, Hartmut, Doyen, Chantal, Kaiser, Martin, Petrini, Mario, Anttila, Pekka, Cafro, Anna Maria, Raymakers, Reinier, San Miguel, Jesús F., Arriba, Felipe de, Knop, Stefan, Röllig, Christoph, Ocio, Enrique M., Morgan, Gareth J., Miller, Neil, Simcock, Mathew, Peluso, Teresa, Herring, Jennifer, Sternas, Lars, Zaki, Mohamed H., Moreau, Philippe, Celgene, Dimopoulos, Meletios A., Palumbo, Antonio, Corradini, Paolo, Cavo, Michele, Delforge, Michel, Di Raimondo, Francesco, Weisel, Katja C., Oriol, Albert, Hansson, Markus, Vacca, Angelo, Blanchard, María Jesús, Goldschmidt, Hartmut, Doyen, Chantal, Kaiser, Martin, Petrini, Mario, Anttila, Pekka, Cafro, Anna Maria, Raymakers, Reinier, San Miguel, Jesús F., Arriba, Felipe de, Knop, Stefan, Röllig, Christoph, Ocio, Enrique M., Morgan, Gareth J., Miller, Neil, Simcock, Mathew, Peluso, Teresa, Herring, Jennifer, Sternas, Lars, Zaki, Mohamed H., and Moreau, Philippe
Abstract: Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients with RRMM. Patients who failed treatment with bortezomib and lenalidomide and had adequate prior alkylator therapy were eligible. Pomalidomide 4 mg was given on days 1-21 of 28-day cycles with low-dose dexamethasone 40 mg (20 mg for patients aged >75 years) on days 1, 8, 15, and 22 until progressive disease or unacceptable toxicity. Safety was the primary end point; secondary end points included overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Among 682 patients enrolled, median age was 66 years, and median time since diagnosis was 5.3 years. Median number of prior regimens was 5. Most patients were refractory to both lenalidomide and bortezomib (80.2%). Median follow-up was 16.8 months; median duration of treatment was 4.9 months. Most frequent grade 3/4 treatment-emergent adverse events were hematologic (neutropenia [49.7%], anemia [33.0%], and thrombocytopenia [24.1%]). Most common grade 3/4 nonhematologic toxicities were pneumonia (10.9%) and fatigue (5.9%). Grade 3/4 venous thromboembolism and peripheral neuropathy were rare (1.6% each). The ORR was 32.6%, and the median DOR was 7.4 months. Median PFS and OS were 4.6 months and 11.9 months, respectively. We present the largest trial to date evaluating pomalidomide plus low-dose dexamethasone in patients with RRMM, further confirming that this regimen offers clinically meaningful benefit and is generally well tolerated.
Published: 2016

150. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM)

Author: Lokhorst, Henk, Laubach, Jacob, Nahi, Hareth, Plesner, Torben, Gimsing, Peter, Hansson, Markus, Minnema, Monique, Lassen, Ulrik, Krejcik, Jakub, Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa, Lisby, Steen, Basse, Linda, C. Brun, Nikolai, and Richardson, Paul
Published: 2014

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

613 results on '"Hansson, Markus"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources